Solventum Corporation (NYSE:SOLV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Solventum Corporation (NYSE:SOLV) have earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $84.25.

Several equities research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Rothschild & Co Redburn assumed coverage on shares of Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 target price for the company. Wedbush assumed coverage on shares of Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, KeyCorp upped their target price on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th.

Solventum Price Performance

SOLV opened at $75.13 on Monday. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum has a 52-week low of $62.38 and a 52-week high of $88.20. The company has a 50 day moving average of $69.57 and a two-hundred day moving average of $75.06. The company has a market cap of $13.01 billion, a P/E ratio of 9.21, a P/E/G ratio of 1.16 and a beta of 0.69.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the firm earned $1.34 earnings per share. Solventum’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts expect that Solventum will post 6.58 earnings per share for the current year.

Insider Buying and Selling at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the purchase, the director owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.24% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Hilltop National Bank boosted its stake in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. CrossGen Wealth LLC purchased a new position in shares of Solventum in the fourth quarter valued at $25,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Solventum in the third quarter valued at $25,000. Clearstead Trust LLC boosted its stake in shares of Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its stake in shares of Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after purchasing an additional 163 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.